Celldex Therapeutics, Inc. — Q2 2023 Form 10-Q
Business context and reporting period
Celldex is a clinical-stage biopharmaceutical company developing antibody therapies for inflammatory diseases and cancer. This unaudited filing covers the quarter and six months ended June 30, 2023. Its lead program, barzolvolimab (CDX-0159), targets KIT and is being studied in mast-cell-driven diseases; CDX-585, a bispecific antibody for solid tumors, entered Phase 1 in May 2023.
Financial performance and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $0.3 million | $0.2 million | $1.2 million | $0.3 million |
| Research and development expense | $26.3 million | $20.7 million | $53.0 million | $37.8 million |
| Operating loss | $33.2 million | $36.4 million | $65.7 million | $59.7 million |
| Net loss | $30.5 million | $36.0 million | $59.9 million | $59.1 million |
| Basic and diluted loss per share | $0.65 | $0.77 | $1.27 | $1.26 |
Revenue was primarily from contract and grant work, including services for Rockefeller University; the company reported no product sales. Gross margin is not meaningful for this business mix. Six-month operating cash use was $55.8 million, versus $46.8 million a year earlier. Investing activities provided $53.7 million, primarily reflecting net marketable-security sales and maturities; financing activities provided $0.8 million. Cash and cash equivalents declined $1.2 million from year-end.
At June 30, cash and cash equivalents were $28.2 million and marketable securities were $224.5 million, totaling $252.7 million. Total liabilities were $21.8 million and stockholders’ equity was $277.5 million. No conventional borrowings are reported; liabilities include lease obligations and other long-term liabilities. Management said resources were sufficient to fund planned operations through 2025, subject in part to whether future SRS settlement milestones are paid in cash.
Changes versus the prior comparable period
- Q2 net loss narrowed by $5.5 million, mainly because Q2 2022 included a $15.0 million litigation-settlement loss; the comparison was partly offset by higher R&D expense and the absence of a prior-year contingent-consideration gain.
- For the first six months, net loss increased by $0.8 million. R&D expense rose $15.3 million, primarily from barzolvolimab trials and manufacturing; higher investment income and the absence of the 2022 settlement loss partly offset the increase.
- Investment and other income increased to $5.8 million for the half-year from $0.6 million, primarily due to higher interest rates and income related to the sale of New Jersey tax benefits.
- Marketable securities were $51.1 million lower than at December 31, 2022, while total cash and marketable securities declined by $52.3 million.
Outlook, commentary, risks, and unusual items
- Management expected Q3/Q4 2023 and 2024 spending to support ongoing and planned Phase 2 studies in chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), eosinophilic esophagitis (EoE), and prurigo nodularis (PN). It anticipated CSU Phase 2 topline data in late 2023 and PN Phase 1b data in Q4 2023, with a Phase 2 subcutaneous PN study planned for early 2024.
- The filing reports positive Phase 1b barzolvolimab CSU results, including symptom improvements through 24 weeks; the company described the treatment as generally well tolerated. Reported adverse events included hair-color changes and neutropenia. These are early-stage results and do not establish efficacy or safety in larger trials.
- Celldex reported that it had completed enrollment of 208 patients in its CSU Phase 2 study in July 2023, after the quarter, and planned late-2023 topline results. A Phase 2 EoE study was initiated in June, with the first patient dosed late that month. CDX-585’s Phase 1 study began in May.
- The 2022 SRS settlement replaced prior Kolltan milestone terms. Potential future payments include $15.0 million upon successful completion of a CDX-0159 Phase 2 trial, subject to a $2.5 million contractual credit, and $52.5 million upon the first qualifying U.S. or European regulatory approval. Payments may be made in cash, stock, or a combination, at Celldex’s option. The initial $15.0 million payment was made in 2022.
- The company reported recurring losses and warned that further financing may be needed for long-term needs. Equity financing could dilute shareholders; debt or partnerships could impose restrictive or economically adverse terms. If funding is inadequate, programs or trials could be delayed, discontinued, or licensed earlier than planned.
- Clinical development, regulatory approval, manufacturing, competition, intellectual property, and the uncertain timing and cost of trials remain key risks. Celldex stated that there were no material changes to the risk factors in its 2022 Form 10-K. It also reported effective disclosure controls and no material change in internal control over financial reporting.
Important facts for investors to verify
- Whether planned CSU and PN readouts occurred on schedule, and how complete Phase 2 data compare with the positive but small Phase 1b results.
- Subsequent operating cash use, R&D spending, and whether management’s stated runway through 2025 remains supportable.
- Trial enrollment, timing, safety findings, and development decisions for CIndU, EoE, PN, and CDX-585.
- Whether SRS milestone triggers are achieved and the amount and form of any resulting payments.
- Future financing, collaboration, or licensing activity and its potential effects on dilution, cash runway, and product economics.